Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity

Size: px
Start display at page:

Download "Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity"

Transcription

1 Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity Cory V. Noel, M.D. Medical Director of CMR Pediatric Cardiology

2 Outline What is meant by the term cardiotoxicity? Scope of the issue of cardiotoxicity Current guidelines for cardiotoxicity detection Advantages of CMR in the identification of cardiotoxicity Integration of CMR into surveillance imaging Page 1 xxx00.#####.ppt 10/11/2017 8:58:56 AM

3 Cancer-Related Cardiotoxicity CV-related disease is leading cause of morbidity and mortality At 30 years of age, over 70% of survivors have chronic health condition Pediatric Cancer and Cardiotoxicity Establishment of a Cardio-Oncology Team 8 x more likely to die of heart disease 15 x more likely to develop HF Risk further increased when used with radiation therapy Oeffinger, et al., NEJM, 2006 Mertens, et al., J Clin Oncol, 2001 Landy, et al., Pediatr Cardiol, 2013d Page 2 xxx00.#####.ppt 10/11/2017 8:58:57 AM

4 Cardiotoxicity Bloom MW, et al., Circulation: Heart Failure, 2016 Page 3 xxx00.#####.ppt 10/11/2017 8:58:57 AM

5 What is meant by Cardiotoxicity? No uniform definition Primarily concerns left ventricular systolic function Commonly used definition is > 5% drop in LVEF with HF symptoms or a > 10% asymptomatic drop to an LVEF below 55% Recent expert consensus for multimodality imaging recommends a decrease to 53% Cardiotoxicity versus Cancer Therapy-Related Cardiac Dysfunction (CTRCD) Seidman, et al., J Clin Oncol, 2002 Plana, et al., JASE, 2014 Page 4 xxx00.#####.ppt 10/11/2017 8:58:57 AM

6 Defining the Issue Cardiotoxicity (NCI) Grade I: Asymptomatic biomarkers or abnormalities on imaging Grade II & III: Symptoms with mild to moderate exertion Grade IV: Severe, life threatening symptoms Grade V: Death Bloom MW, et al., Circulation: Heart Failure, 2016 CTRCD (ESC, ASE) Decrease in LVEF of > 10% to a value below 53%... Confirmed by repeat imaging Reversible if return to within 5% of baseline Partial if improved by 10%, but not within 5% of baseline Irreversible if improved <10%, and remains > 5% from baseline Page 5 xxx00.#####.ppt 10/11/2017 8:58:57 AM

7 Scope of the Issue With variable definition, true prevalence is difficult to quantify Studies often do not account for baseline risks Bloom MW, et al., Circulation: Heart Failure, 2016 Page 6 xxx00.#####.ppt 10/11/2017 8:58:57 AM

8 Timing of Cardiac Effect Acute toxicity (within 1 week) Uncommon (~1%), generally reversible Early-onset chronic form (within 1 year) Peak incidence in 3 months ( %) Typically irreversible Late-onset chronic form (after 1 year) years (1.6 5%) Typically irreversible Bloom MW, et al., Circulation: Heart Failure, 2016 Wickramasinghe CD, et al., Future Oncology, 2016 Page 7 xxx00.#####.ppt 10/11/2017 8:58:57 AM

9 Scope of the Issue Reasonable prevalence of early and late-onset chronic dysfunction Several risk factors playing a role Likely much higher prevalence of asymptomatic dysfunction that could be detected with improved surveillance Page 8 xxx00.#####.ppt 10/11/2017 8:58:57 AM

10 Importance of Early Detection St. Jude Lifetime Cohort 1853 adult survivors of childhood cancer Median age of 8 years at time of diagnosis Median age of 31 years at evaluation Mulrooney D, et al., Annals of Internal Medicine, 2016 Page 9 xxx00.#####.ppt 10/11/2017 8:58:58 AM

11 Evaluation of LV Function Curigliano, et al., Annals of Oncol, 2012 Page 10 xxx00.#####.ppt 10/11/2017 8:58:58 AM

12 Variability with Echo Assessment Plana, et al., JASE, 2014 Page 11 xxx00.#####.ppt 10/11/2017 8:58:58 AM

13 Variability of Echo Assessment Commonly used definition of > 5% drop in LVEF with HF symptoms or a > 10% asymptomatic drop to an LVEF below 55% Longitudinal variability of 2D LVEF is about 10% Page 12 xxx00.#####.ppt 10/11/2017 8:58:58 AM

14 Cardiac MRI versus Echo 114 adult survivors of childhood cancer 14% shown to have LVEF < 50% by CMR 2D echo overestimated the LVEF by 5% Armstrong, et al., J of Clin Oncol, 2012 Page 13 xxx00.#####.ppt 10/11/2017 8:58:58 AM

15 Integration of Cardiac MRI Unable to obtain accurate baseline assessment Confirmation of significant LVEF drop or value below 55% When considering holding or stopping cancerrelated therapy When complete with cancer-related therapy Risk-based intervals in long-term surveillance Page 14 xxx00.#####.ppt 10/11/2017 8:58:58 AM

16 Is There a Need for Earlier Detection? Is it possible to improve predictive analysis on which patients will develop heart failure and CTRCD? Page 15 xxx00.#####.ppt 10/11/2017 8:58:58 AM

17 Limitations of LVEF Relatively insensitive tool for detecting early damage Myocardial changes occur at doses below those typically associated with a drop in LVEF Morphological continuum of myocardial injury A drop in the LVEF appears to be a relatively late event in the cardiotoxicity cascade Ewer, et al., J of Clin Oncol, 1984 Cross, et al., Brit J of Pharm., 2015 Suter, et al., Euro Heart Journ., 2013 Page 16 xxx00.#####.ppt 10/11/2017 8:58:59 AM

18 Early Detection of Cardiac Dysfunction Allow for earlier identification of cardiac changes, particularly in cases of acute or early forms of cardiotoxicity Modify treatment regimen if needed Identify patients that may require more frequent surveillance imaging Goal to identify non-invasive imaging biomarkers to predict ventricular dysfunction Page 17 xxx00.#####.ppt 10/11/2017 8:58:59 AM

19 Importance of Early Detection Cardinale D, et al., JACC, 2010 Page 18 xxx00.#####.ppt 10/11/2017 8:58:59 AM

20 Utility of MRI in Early Detection Early anthracycline toxicity associated with inflammation, vacuolization and cardiomyocyte edema These changes occur before myocardial functional abnormalities Later stages of toxicity associated with fibrosis MRI offers the ability of myocardial characterization Regional wall deformation assessment Kajihara, et al., Pathol Res Pract, 1986 Friedman, et al., JAMA, 1978 Cottin, et al., Can J of Pharm, 1994 Page 19 xxx00.#####.ppt 10/11/2017 8:58:59 AM

21 Utility of MRI in Early Detection Cross, et al., Brit J of Pharm, 2015 Meyersohn N, et al., Curr Treat Options Cardio Med, 2015 Page 20 xxx00.#####.ppt 10/11/2017 8:58:59 AM

22 CMR Myocardial Characterization T2 T2 maps and weighted imaging is sensitive to both regional and global myocardial edema Myocardial edema occurs as a result of acute injury Edema occurs relatively early in the myocardial cascade prior to cardiomyocyte necrosis Mirakhur, et al., Euro J of Radiol, 2013 Francone, et al., Radiol Medicine, 2011 Page 21 xxx00.#####.ppt 10/11/2017 8:58:59 AM

23 CMR Myocardial Characterization T2 Mirakhur, et al., Euro J of Radiol, 2013 Thavendiranathan, et al., Circ Imaging, 2013 Page 22 xxx00.#####.ppt 10/11/2017 8:58:59 AM

24 CMR Myocardial Characterization T2 Smith et al have illustrated in 28 breast CA patients that increased SI on day 3 associated with drop in LVEF at 1 year Grover et al examined 46 breast CA patients 49% had abnormal T2 consistent with myocardial edema at 1 or 4 months after therapy commencement Thavendiranathan, et al., Circ Imaging, 2015 Grover, et al., Int J of Cardiol, 2013 Page 23 xxx00.#####.ppt 10/11/2017 8:59:00 AM

25 65 adult patients treated with anthracyclines CMR prior to and 3 months following chemo LVEF had a small but significant decline over the 3 month span (57±6% to 54±7%) T1-weighted imaging occurs diffusely and is associated with the drop in LVEF T2 imaging likely affected by timing of CMR Jordan, et al., Circ. Imaging, 2014 Page 24 xxx00.#####.ppt 10/11/2017 8:59:00 AM

26 Extracellular Volume Quantification Utilizes myocardial and blood T1 times, as well as hematocrit to calculate ECV fraction Highly accurate detection of diffuse myocardial fibrosis Moon JC, et al., JCMR, 2013 Ugander M, et al., Euro Heart J, 2012 Wong T, et al., Circulation, 2012 Page 25 xxx00.#####.ppt 10/11/2017 8:59:00 AM

27 CMR Myocardial Characterization T1 Schelbert E, et al., Radiology, 2016 Page 26 xxx00.#####.ppt 10/11/2017 8:59:01 AM

28 Extracellular Volume Quantification Shelbert E, et al., Journal of AHA, 2016 Kammerlander A, et al., JACC: Imaging, 2016 Page 27 xxx00.#####.ppt 10/11/2017 8:59:01 AM

29 CMR Myocardial Characterization T1 Jordan J, et al., Circulation: Imaging., 2016 Page 28 xxx00.#####.ppt 10/11/2017 8:59:01 AM

30 CMR Myocardial Characterization T1 Jordan J, et al., Circulation: Imaging., 2016 Page 29 xxx00.#####.ppt 10/11/2017 8:59:02 AM

31 CMR Regional Wall Motion Analysis Assessment of myocardial strain that may depict a decrease in myocardial function prior than EF Evaluation of 46 longterm childhood CA survivors Normal LVEF by echo Lower T1 values Toro-Salazar, et al., Circ Imaging, 2013 Page 30 xxx00.#####.ppt 10/11/2017 8:59:02 AM

32 Current Clinical Study 10 patients with diagnosis of solid bone tumor and expected anthracycline dose > 250 mg/m^2 CMR baseline prior to chemotherapy initiation mg/m^2 12 months following final chemotherapy administration Exercise stress test with VO2 calculation at 12 months Page 31 xxx00.#####.ppt 10/11/2017 8:59:02 AM

33 Protocol Multiplanar Survey Cine Sequences btfe VLA, 4-Chamber, SAX Volumetric and Functional Quantification LV Mass T2 and Native T1 Mapping 45 minutes SPAMM and fsenc Myocardial Deformation Rest perfusion 1.5 Dose Gadobutrol Delayed Enhancement T1 Mapping and ECV Quantification Page 32 xxx00.#####.ppt 10/11/2017 8:59:02 AM

34 Patient Page 33 xxx00.#####.ppt 10/11/2017 8:59:02 AM

35 Myocardial Characterization by CMR Page 34 xxx00.#####.ppt 10/11/2017 8:59:03 AM

36 Myocardial Characterization by CMR Page 35 xxx00.#####.ppt 10/11/2017 8:59:03 AM

37 Myocardial Characterization by CMR Page 36 xxx00.#####.ppt 10/11/2017 8:59:03 AM

38 Potential Future Incorporation of CMR Utilization for early detection based upon myocardial characterization and myocardial strain Utilization in long-term survivors for prognosis with ECV and determining future surveillance Page 37 xxx00.#####.ppt 10/11/2017 8:59:03 AM

39 Thank you Page 38 xxx00.#####.ppt 10/11/2017 8:59:03 AM

Cardio-oncology: Applying new echo technology to guide therapy

Cardio-oncology: Applying new echo technology to guide therapy Cardio-oncology: Applying new echo technology to guide therapy Dinesh Thavendiranathan MD, SM, FRCPC, FASE Director, Ted Rogers Program in Cardiotoxicity Prevention Assistant Professor of Medicine Division

More information

How to Evaluate the Heart of Elderly Patients

How to Evaluate the Heart of Elderly Patients How to Evaluate the Heart of Elderly Patients Special considerations regarding cardiotoxicity Michael S. Ewer MD The University of Texas M. D. Anderson Cancer Center Why Discuss Cardiac Disease and Cancer

More information

Disclosures. Objectives. SK continued. Two of my patients. First and foremost, why is this important??? 10/26/2016

Disclosures. Objectives. SK continued. Two of my patients. First and foremost, why is this important??? 10/26/2016 Disclosures Bayer Pharmaceuticals: clinical trial investigator KellyAnn Light-McGroary, MD, FACC Clinical Assistant Professor Cardiomyopathy Treatment Program University of Iowa Hospitals and Clinics Chief

More information

Guideline-Driven Care in Cardio- Oncology: Utilizing Recommendations Across Disciplines

Guideline-Driven Care in Cardio- Oncology: Utilizing Recommendations Across Disciplines Guideline-Driven Care in Cardio- Oncology: Utilizing Recommendations Across Disciplines Jennifer Liu, MD FACC FASE Director of CV Laboratories Associate Professor of Clinical Medicine Memorial Sloan Kettering

More information

CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long

CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Albert

More information

Building a Cardio-Oncology Program

Building a Cardio-Oncology Program Building a Cardio-Oncology Program Marielle Scherrer-Crosbie, MD, PhD Professor of Medicine Director of Echocardiography University of Pennsylvania Philadelphia, PA Co-Director, Cardio-Oncology Program

More information

Advanced Echocardiography in the Evaluation of Chemotherapy Patients

Advanced Echocardiography in the Evaluation of Chemotherapy Patients Advanced Echocardiography in the Evaluation of Chemotherapy Patients Juan Carlos Plana, MD, FACC, FASE Co-Director, Cardio-Oncology Center Section of Cardiovascular Imaging Department of Cardiovascular

More information

Cancer and the heart: New evidence and open issues

Cancer and the heart: New evidence and open issues Cancer and the heart: New evidence and open issues Dimitrios Farmakis, MD, PhD, FESC Assist. Professor, European University Cyprus Cardio-Oncology Clinic, Heart Failure Unit, Attikon Hospital Cardiac Clinic

More information

Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics

Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics Richard Sheppard MD FRCPC Director of Heart Failure Research Heart Function Clinic Jewish General hospital Objectives 1. Discuss

More information

HFPEF Echo with Strain vs. MRI T1 Mapping

HFPEF Echo with Strain vs. MRI T1 Mapping HFPEF Echo with Strain vs. MRI T1 Mapping Erik Schelbert, MD MS Director, Cardiovascular Magnetic Resonance Assistant Professor of Medicine Heart & Vascular Institute University of Pittsburgh Disclosures

More information

Cardiotoxicity Effects of Chemotherapeutic Drugs

Cardiotoxicity Effects of Chemotherapeutic Drugs Cardiotoxicity Effects of Chemotherapeutic Drugs Allan L Klein M.D. Director, Center of Pericardial Diseases Professor of Medicine Heart and Vascular Institute Cleveland Clinic President, ASE * No conflicts

More information

Cardio oncology Double Jeopardy

Cardio oncology Double Jeopardy Cardio oncology Double Jeopardy Edie Pituskin RN MN (NP Adult) PhD NP Forum for Nursing and Allied Health, April 10, 2015 Aims Describe the double jeopardy faced by cancer patients Discuss issues in detection

More information

Cured of Cancer but now Let s Heal the Heart An exploration into the effects of cancer on the heart

Cured of Cancer but now Let s Heal the Heart An exploration into the effects of cancer on the heart Cured of Cancer but now Let s Heal the Heart An exploration into the effects of cancer on the heart Suma H. Konety, MD, MS Associate Professor, Cardiovascular Division University of Minnesota What is Cardio-Oncology?

More information

IRM cardiaque en cancérologie: le rôle du radiologue

IRM cardiaque en cancérologie: le rôle du radiologue IRM cardiaque en cancérologie: le rôle du radiologue Laurent MACRON Centre Cardiologique du Nord (CCN) Saint Denis Centre Cardiologique du Nord - Saint Denis - France CMR in oncology Characterisation of

More information

Cardiovascular Imaging Endpoints in Oncology Clinical Trials

Cardiovascular Imaging Endpoints in Oncology Clinical Trials Cardiovascular Imaging Endpoints in Oncology Clinical Trials Bonnie Ky, MD, MSCE Assistant Professor of Medicine and Epidemiology Director, Penn Cardio-Oncology Center of Excellence Director, Penn Center

More information

Strain Imaging: Myocardial Mechanics Simplified and Applied

Strain Imaging: Myocardial Mechanics Simplified and Applied 9/28/217 Strain Imaging: Myocardial Mechanics Simplified and Applied John Gorcsan III, MD Professor of Medicine Director of Clinical Research Division of Cardiology VECTORS OF CONTRACTION Shortening Thickening

More information

Can point of care cardiac biomarker testing guide cardiac safety during oncology trials?

Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University

More information

03/14/2019. Scope of the Problem. Objectives

03/14/2019. Scope of the Problem. Objectives Cardiac Consideration During and After Breast Cancer Treatment Indu G. Poornima M.D Division of Cardiology Scope of the Problem 1 in 8 women will develop breast cancer 3.3 million women are survivors CVD

More information

Cardio-oncology: Basics and Knowing When You Need an Echo

Cardio-oncology: Basics and Knowing When You Need an Echo Cardio-oncology: Basics and Knowing When You Need an Echo Vera H. Rigolin, MD, FASE, FACC, FAHA Professor of Medicine Northwestern University Feinberg School of Medicine Medical Director, Echocardiography

More information

Cardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient

Cardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient Cardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient Vijay U. Rao, MD, PhD, FACC, FASE Franciscan Physician Network Indiana Heart Physicians Director, Franciscan Health Inpatient Heart

More information

CT for Myocardial Characterization of Cardiomyopathy. Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea

CT for Myocardial Characterization of Cardiomyopathy. Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea CT for Myocardial Characterization of Cardiomyopathy Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea Cardiomyopathy Elliott P et al. Eur Heart J 2008;29:270-276 The European Society

More information

Cancer survivors. Half of Cancer Survivors Die of Other Conditions. Cause of Death in Cancer Survivors

Cancer survivors. Half of Cancer Survivors Die of Other Conditions. Cause of Death in Cancer Survivors Cardiotoxicity of Cancer Therapies: Pathogenesis, Diagnosis, and Management Edward T.H. Yeh, M.D. Cancer survivors Now nearly 12 million cancer survivors in U.S. according to NCI 15% were diagnosed 2+

More information

Potpourri: Cardio-Oncology Cases

Potpourri: Cardio-Oncology Cases Potpourri: Cardio-Oncology Cases Judy Hung, MD Massachusetts General Hospital Harvard Medical School No disclosures; Thank Michael Picard and Tomas Neilan for cases 59 year old woman (sister diagnosed

More information

VECTORS OF CONTRACTION

VECTORS OF CONTRACTION 1/3/216 Strain, Strain Rate, and Torsion: Myocardial Mechanics Simplified and Applied VECTORS OF CONTRACTION John Gorcsan, MD University of Pittsburgh, Pittsburgh, PA Shortening Thickening Twisting No

More information

Anthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients

Anthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients Anthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients Scottish Cancer Trials Breast Group Meeting Thursday 2 nd February 2017 Dr Peter Henriksen Edinburgh Heart Centre

More information

Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy

Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy JEAN-BERNARD DURAND, M.D., FCCP, FACC,FACP,FHFSA,FAHA PROFESSOR OF MEDICINE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

More information

CardioOncology: The Promise and Pitfalls of Personalized Medicine

CardioOncology: The Promise and Pitfalls of Personalized Medicine CardioOncology: The Promise and Pitfalls of Personalized Medicine Vijay U. Rao, MD, PhD, FACC, FASE, FHFSA Franciscan Physician Network Indiana Heart Physicians Director, Franciscan Health Inpatient Heart

More information

Chemotherapy- Associated Heart Failure. M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY

Chemotherapy- Associated Heart Failure. M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY Chemotherapy- Associated Heart Failure M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY In last 20 years life-expectancy for patients with cancer

More information

Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer

Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer Dr. Chris Fryer, Pediatric Oncologist, BC Children s Hospital Dr. Sean Virani, Founding Director, UBC Cardiovascular Oncology

More information

Multiparametric T1, T2 and T2* MR Imaging

Multiparametric T1, T2 and T2* MR Imaging Multiparametric T1, T2 and T2* MR Imaging Kate Hanneman MD Assistant Professor of Radiology Joint Department of Medical Imaging, University of Toronto Disclosure Neither I nor my immediate family members

More information

Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx

Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx 5 th Annual Echo Florida, October 2016 Vincent L. Sorrell, MD Anthony N. DeMaria Professor of Medicine (Card/ Rad) University

More information

Cardiotoxicity: The View of the Cardiologist

Cardiotoxicity: The View of the Cardiologist Cardiotoxicity: The View of the Cardiologist Dr. Yael Peled, Cardio-Oncology Interactions: 1.Cardiotoxicity following chemotherapy 2. Co existence of cancer and CVD Aging & common risk factors cardiac

More information

Imaging and heart failure

Imaging and heart failure Imaging and heart failure Jeroen J Bax Dept of Cardiology Leiden Univ Medical Center The Netherlands Davos, feb 2013 Research grants: Medtronic, Biotronik, Boston, St Jude, BMS imaging, GE Healthcare,

More information

Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου. Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα

Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου. Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα Estimated and projected cancer survivors in USA de Moor JS et al. Cancer Epidemiol Biomarkers Prev 2013 Causes of

More information

Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx. No Real or Potential Conflict of Interests for this Talk CTRCD

Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx. No Real or Potential Conflict of Interests for this Talk CTRCD Expert Consensus for MMI Evaluation of Adult Patients During and After Cancer Rx Vincent L. Sorrell, MD Anthony N. DeMaria Professor of Medicine University of Kentucky / Gill Heart & Vascular Institute

More information

Ian Paterson, Mazankowski Alberta Heart Institute Division of Cardiology, University of Alberta

Ian Paterson, Mazankowski Alberta Heart Institute Division of Cardiology, University of Alberta Ian Paterson, Mazankowski Alberta Heart Institute Division of Cardiology, University of Alberta Peer Reviewed Funding: CIHR, ACF, AI-HS Industry: Servier Canada Inc, RocheCanada Inc. What is your approach

More information

Tissue Doppler and Strain Imaging

Tissue Doppler and Strain Imaging Tissue Doppler and Strain Imaging Steven J. Lester MD, FRCP(C), FACC, FASE Relevant Financial Relationship(s) None Off Label Usage None 1 Objective way with which to quantify the minor amplitude and temporal

More information

Managing LV Impairment with Cancer Therapies

Managing LV Impairment with Cancer Therapies British Society for Heart Failure Revalidation & Training Day London, March 2017 Managing LV Impairment with Cancer Therapies Zaheer Yousef BSc MBBS MD FESC FRCP Heart Muscle Diseases & Heart Function

More information

Cardiac magnetic resonance imaging in rheumatoid arthritis: promising or misleading? Sophie Mavrogeni MD FESC

Cardiac magnetic resonance imaging in rheumatoid arthritis: promising or misleading? Sophie Mavrogeni MD FESC Cardiac magnetic resonance imaging in rheumatoid arthritis: promising or misleading? Sophie Mavrogeni MD FESC Onassis Cardiac Surgery Center Athens Greece Nothing to disclose Financial disclosure Cardiac

More information

Cardio-Oncology at MHI. Kasia Hryniewicz, M.D.

Cardio-Oncology at MHI. Kasia Hryniewicz, M.D. Minneapolis Heart Institute at Abbott Northwestern Hospital Cardio-Oncology at MHI Cardiovascular Nursing Conference Kasia Hryniewicz, M.D. October 7 th, 2015 No disclosure 1 Why cardio-oncology? Background

More information

Clinical Policy Title: Echocardiographic assessment of myocardial strain for cancer patients

Clinical Policy Title: Echocardiographic assessment of myocardial strain for cancer patients Clinical Policy Title: Echocardiographic assessment of myocardial strain for cancer patients Clinical Policy Number: 04.01.07 Effective Date: April 1, 2016 Initial Review Date: November 18, 2015 Most Recent

More information

New Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care

New Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care New Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care Sandra M Swain, MD, FACP, FASCO Professor of Medicine Associate Dean for Research Development Georgetown

More information

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED) A Light in the Dark: Cardiac MRI and Risk Mitigation J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED) Dr. Mikolich has NO financial disclosures relative to

More information

Tissue Doppler and Strain Imaging

Tissue Doppler and Strain Imaging Tissue Doppler and Strain Imaging Steven J. Lester MD, FRCP(C), FACC, FASE Relevant Financial Relationship(s) None Off Label Usage None 1 Objective way with which to quantify the minor amplitude and temporal

More information

Cardiology for the Practitioner Advanced Cardiac Imaging: Worth the pretty pictures?

Cardiology for the Practitioner Advanced Cardiac Imaging: Worth the pretty pictures? Keenan Research Centre Li Ka Shing Knowledge Institute Cardiology for the Practitioner Advanced Cardiac Imaging: Worth the pretty pictures? Howard Leong-Poi, MD, FRCPC Associate Professor of Medicine St.

More information

Strain and Strain Rate Imaging How, Why and When?

Strain and Strain Rate Imaging How, Why and When? Strain and Strain Rate Imaging How, Why and When? João L. Cavalcante, MD Advanced Cardiac Imaging Fellow Cleveland Clinic Foundation Disclosures: No conflicts of interest Movement vs Deformation Movement

More information

Cardiac Health in Duchenne: What we are Learning from Cardiac MRI

Cardiac Health in Duchenne: What we are Learning from Cardiac MRI Cardiac Health in Duchenne: What we are Learning from Cardiac MRI 24 th Annual Duchenne Connect Conference Parent Project Muscular Dystrophy Scottsdale, AZ June 29, 2018 Kan N. Hor, MD Director of Cardiac

More information

What s New in Cardiac MRI

What s New in Cardiac MRI What s New in Cardiac MRI Katie M. Hawthorne, MD Director, Cardiac MRI Main Line Health Philadelphia Cardiovascular Summit November 18, 2017 Cardiac MRI: Disclosure 2 Disclosures No financial disclosures

More information

Cardiovascular outcomes in survivors of childhood cancer

Cardiovascular outcomes in survivors of childhood cancer Cardiovascular outcomes in survivors of childhood cancer Paul Nathan MD, MSc Director, AfterCare Program Division of Haematology/Oncology The Hospital for Sick Children, Toronto Conflicts Nothing to declare

More information

Clinical Perspective: How Are We Doing From a Clinician s Point of View

Clinical Perspective: How Are We Doing From a Clinician s Point of View Clinical Perspective: How Are We Doing From a Clinician s Point of View Steven E. Lipshultz, MD Department of Pediatrics University of Miami Miller School of Medicine Holtz Children s Hospital of the University

More information

It s not just the chemo a case of exertional dyspnoea in a Hodgkin survivor.

It s not just the chemo a case of exertional dyspnoea in a Hodgkin survivor. It s not just the chemo a case of exertional dyspnoea in a Hodgkin survivor. V Aggelis 1 MRCP M Westwood 1,2 MBBS MD FRCP FESC G Lloyd 1 MBBS MD FRCP S Hallam 3 MA PhD MRCP FRCPath AK Ghosh 1,2 MBBS MRCP

More information

Outils d évaluation myocardique par relaxométrie (Myomaps)

Outils d évaluation myocardique par relaxométrie (Myomaps) Cardiovascular sciences Outils d évaluation myocardique par relaxométrie (Myomaps) Alain Nchimi Geva T. Magnetic resonance imaging: historical perspective. J Cardiovasc Magn Reson. 2006;8(4):573-80. CMR

More information

Usefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity

Usefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity Usefulness of Delayed Enhancement by Magnetic Resonance Imaging in Hypertrophic Cardiomyopathy as a Marker of Disease and Its Severity G.D.Aquaro, MD Fondazione G.Monasterio Regione Toscana/CNR Pisa, Italy

More information

Valvular Regurgitation: Can We Do Better Than Colour Doppler?

Valvular Regurgitation: Can We Do Better Than Colour Doppler? Valvular Regurgitation: Can We Do Better Than Colour Doppler? A/Prof David Prior St Vincent s Hospital Melbourne Sports Cardiology Valvular Regurgitation Valve regurgitation volume loads the ventricles

More information

RECONCILING GUIDELINES, RECOMMENDATIONS AND CONSENSUS STATEMENTS TO PROVIDE OPTIMAL CARDIO-ONCOLOGY CARE

RECONCILING GUIDELINES, RECOMMENDATIONS AND CONSENSUS STATEMENTS TO PROVIDE OPTIMAL CARDIO-ONCOLOGY CARE RECONCILING GUIDELINES, RECOMMENDATIONS AND CONSENSUS STATEMENTS TO PROVIDE OPTIMAL CARDIO-ONCOLOGY CARE SARO ARMENIAN, DO, MPH ASSOCIATE PROFESSOR, DEPARTMENTS OF PEDIATRICS AND POPULATION SCIENCES DIRECTOR,

More information

Cardiotoxicities of Cancer in Childhood Cancer Survivors

Cardiotoxicities of Cancer in Childhood Cancer Survivors Cardiotoxicities of Cancer in Childhood Cancer Survivors Steven E. Lipshultz, MD Department of Pediatrics Wayne State University School of Medicine Children s Hospital of Michigan Detroit, MI, USA Stages

More information

Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure

Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure Diastolic Dysfunction: Hypertension to Hypertrophy to Heart Failure Dr. Shelley Zieroth FRCPC Assistant Professor, Cardiology, University of Manitoba Director of Cardiac Transplant and Heart Failure Clinics

More information

Breast Cancer and the Heart

Breast Cancer and the Heart Breast Cancer and the Heart Anne H. Blaes, M.D., M.S. Associate Professor University of Minnesota Hematology/Oncology Director, Adult Cancer Survivor Clinic No disclosures Objectives Discuss cardiac complications

More information

Cardiovascular Imaging Stress Echo

Cardiovascular Imaging Stress Echo Cardiovascular Imaging Stress Echo Theodora A Zaglavara, MD, PhD Cardiac Imaging Department INTERBALKAN MEDICAL CENTER Thessaloniki GREECE Evolution of Stress Echo: From Innovation to a Widely Established

More information

Γυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI

Γυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI Γυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI Οικογενειακό ιστορικό νεοπλασιών: αρνητικό Σύντομο ατομικό ιστορικό:

More information

Current Guidelines for Diagnosis of AMI Chest pain ST change on EKG Cardiac Enzymes

Current Guidelines for Diagnosis of AMI Chest pain ST change on EKG Cardiac Enzymes Noninvasive Cardiac Imaging in Myocardial Infarction Sangchol Lee Sungkyunkwan University Samsung Medical Center Current Guidelines for Diagnosis of AMI Chest pain ST change on EKG Cardiac Enzymes Do We

More information

Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline

Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline J Clin Oncol. 2016 Dec 5:JCO2016705400. [Epub ahead of print] Objectives: Improve the quality

More information

DECLARATION OF CONFLICT OF INTEREST

DECLARATION OF CONFLICT OF INTEREST DECLARATION OF CONFLICT OF INTEREST Cardiovascular magnetic resonance for timing pulmonary valve replacement E.Valsangiacomo Buechel University Children s Hospital Zurich Outline Introduction Pulmonary

More information

Roohi Ismail-Khan, MD, MS

Roohi Ismail-Khan, MD, MS Roohi Ismail-Khan, MD, MS Associate Member Department of Breast Oncology H. Lee Moffitt Cancer Center Associate Professor University of South Florida Department of Oncological Sciences September 27, 2018

More information

Children s Oncology Group Long-Term Follow- Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Matt Ehrhardt, MD, MS

Children s Oncology Group Long-Term Follow- Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Matt Ehrhardt, MD, MS Children s Oncology Group Long-Term Follow- Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers Matt Ehrhardt, MD, MS Evidence-Based Guidelines for Childhood Cancer Survivors:

More information

Imaging in Heart Failure: A Multimodality Approach. Thomas Ryan, MD

Imaging in Heart Failure: A Multimodality Approach. Thomas Ryan, MD Imaging in Heart Failure: A Multimodality Approach Thomas Ryan, MD Heart Failure HFrEF HFpEF EF50% Lifetime risk 20% Prevalence 6M Americans Societal costs - $30B 50% 5-year survival 1 Systolic

More information

XVth Balkan Congress of Radiology Danubius Hotel Helia, October 2017, Budapest, Hungary

XVth Balkan Congress of Radiology Danubius Hotel Helia, October 2017, Budapest, Hungary XVth Balkan Congress of Radiology Danubius Hotel Helia, 12-14 October 2017, Budapest, Hungary Ružica Maksimović MRI in Myocarditis Faculty of Medicine, University of Belgrade, Centre for Radiology and

More information

International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: , ISSN(Online): Vol.11 No.

International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: , ISSN(Online): Vol.11 No. International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11 No.03, pp 38-43, 2018 Association between Left Ventricular Global Longitudinal Strain and

More information

2019 Qualified Clinical Data Registry (QCDR) Performance Measures

2019 Qualified Clinical Data Registry (QCDR) Performance Measures 2019 Qualified Clinical Data Registry (QCDR) Performance Measures Description: This document contains the 18 performance measures approved by CMS for inclusion in the 2019 Qualified Clinical Data Registry

More information

Advanced imaging of the left atrium - strain, CT, 3D, MRI -

Advanced imaging of the left atrium - strain, CT, 3D, MRI - Advanced imaging of the left atrium - strain, CT, 3D, MRI - Monica Rosca, MD Carol Davila University of Medicine and Pharmacy, Bucharest, Romania Declaration of interest: I have nothing to declare Case

More information

Imaging of cardio-pulmonary treatment related damage. Radiotheraphy and Lung

Imaging of cardio-pulmonary treatment related damage. Radiotheraphy and Lung Imaging of cardio-pulmonary treatment related damage Dr. Andrea Borghesi Dr. Emanuele Gavazzi Department of Radiology 2 University of Brescia Radiotheraphy and Lung The goal of radiation therapy (RT) is

More information

How to Assess Dyssynchrony

How to Assess Dyssynchrony How to Assess Dyssynchrony Otto A. Smiseth, Professor, MD, PhD Oslo University Hospital None Conflicts of interest Cardiac resynchronization therapy effect on mortality Cleland JG et al, N Engl J Med

More information

What the Cardiologist needs to know from Medical Images

What the Cardiologist needs to know from Medical Images What the Cardiologist needs to know from Medical Images Gerald Maurer Department of Cardiology Medical University of Vienna What kinds of Cardiologists Plumbers Electricians Photographers And then there

More information

Importance of CRT team for optimization of the results: a European point of view

Importance of CRT team for optimization of the results: a European point of view Importance of CRT team for optimization of the results: a European point of view Matteo Bertini, MD, PhD Arcispedale S. Anna Azienda Ospedaliero-Universitaria Cona-Ferrara No conflict of interest to declare

More information

Why Cardiac MRI? Presented by:

Why Cardiac MRI? Presented by: Why Cardiac MRI? Presented by: Lisa G. Carkner, MD, FACC 1 Disclosures I have no financial disclosures Objectives Review basic principles of Cardiac MRI. What patient characteristics do I need to consider

More information

When is strain assessment mandatory?

When is strain assessment mandatory? When is strain assessment mandatory? Geneviève Derumeaux University of Lyon France Presenter Disclosure Information Geneviève Derumeaux When is strain assessment mandatory? DISCLOSURE INFORMATION: None

More information

17 th Annual Benjamin Schuster, MD Colloquium February 22 nd, 2017:

17 th Annual Benjamin Schuster, MD Colloquium February 22 nd, 2017: 17 th Annual Benjamin Schuster, MD Colloquium February 22 nd, 2017: Cardiovascular Oncology in 2017: Radiation induced CV Disease Survivorship John Groarke MBBCh MSc MPH Instructor of Medicine, Harvard

More information

The Road to Improve Cardiovascular Health after Cancer. S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018

The Road to Improve Cardiovascular Health after Cancer. S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018 The Road to Improve Cardiovascular Health after Cancer S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018 Objective What are the cardiac complications in cancer

More information

Right ventricular adaptation in endurance athletes. António Freitas. No conflict of interest

Right ventricular adaptation in endurance athletes. António Freitas. No conflict of interest The role of echocardiography in sports cardiology Right ventricular adaptation in endurance athletes. António Freitas Cardiology Department - Fernando Fonseca Hospital Lisbon Sports Medicine Centre - Lisbon

More information

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine

More information

Νεότερα ςτην Υπερηχοκαρδιογραφία. Βαςίλειοσ Καμπερίδησ Clinical research fellow in Cardiology

Νεότερα ςτην Υπερηχοκαρδιογραφία. Βαςίλειοσ Καμπερίδησ Clinical research fellow in Cardiology Νεότερα ςτην Υπερηχοκαρδιογραφία Βαςίλειοσ Καμπερίδησ Clinical research fellow in Cardiology Disclosures ESC training grant EACVI research grant HCS training grant ELIKAR research grant Evolution of Echocardiography

More information

Functional aspects of anatomical imaging techniques

Functional aspects of anatomical imaging techniques Functional aspects of anatomical imaging techniques Nilendu Purandare Associate Professor & Consultant Radiologist Tata Memorial Centre Functional/metabolic/molecular imaging (radioisotope scanning) PET

More information

Advanced Cardiac Imaging in Heart Failure Echo and MRI Beyond the LVEF

Advanced Cardiac Imaging in Heart Failure Echo and MRI Beyond the LVEF West Virginia Am Coll Cardiol Sci Sessions, April, 2016 Advanced Cardiac Imaging in Heart Failure Echo and MRI Beyond the LVEF Vincent L. Sorrell, MD DeMaria Professor of Medicine (Card/ Rad) University

More information

How To Perform Strain Imaging; Step By Step Approach. Maryam Bo Khamseen Echotechnoligist II EACVI, ARDMS, RCS King Abdulaziz Cardiac Center- Riyadh

How To Perform Strain Imaging; Step By Step Approach. Maryam Bo Khamseen Echotechnoligist II EACVI, ARDMS, RCS King Abdulaziz Cardiac Center- Riyadh How To Perform Strain Imaging; Step By Step Approach Maryam Bo Khamseen Echotechnoligist II EACVI, ARDMS, RCS King Abdulaziz Cardiac Center- Riyadh Outlines: Introduction Describe the basic of myocardium

More information

Assessment of Ischemia and Viability

Assessment of Ischemia and Viability EAE Teaching Course Bucharest, 2010 Assessment of Ischemia and Viability Jens-Uwe Voigt Dpt. of Cardiology University Leuven Belgium Assessment of Ischemia & Viability resting wall motion Stress Testing

More information

Cardiac Stress MRI: Detection of Ischemia. Disclosures: Dobutamine Stress MR. April 28, 2018

Cardiac Stress MRI: Detection of Ischemia. Disclosures: Dobutamine Stress MR. April 28, 2018 Cardiac MRI: Detection of Ischemia Cardiac MRI in Today s Clinical Practice Foundations of Cardiovascular Magnetic Resonance Daniel C. Lee, MD, MSc Assistant Professor of Medicine and Radiology Co-Director,

More information

The best from Euro-Echo Ischemic heart disease. Fausto Rigo,FESC Department of Cardiology Mestre-Venezia Hospital,Italy

The best from Euro-Echo Ischemic heart disease. Fausto Rigo,FESC Department of Cardiology Mestre-Venezia Hospital,Italy The best from Euro-Echo 2011 Ischemic heart disease Fausto Rigo,FESC Department of Cardiology Mestre-Venezia Hospital,Italy faustorigo@alice.it DECLARATION OF CONFLICT OF INTEREST No conflict of interest

More information

10/7/2013. Systolic Function How to Measure, How Accurate is Echo, Role of Contrast. Thanks to our Course Director: Neil J.

10/7/2013. Systolic Function How to Measure, How Accurate is Echo, Role of Contrast. Thanks to our Course Director: Neil J. Systolic Function How to Measure, How Accurate is Echo, Role of Contrast Neil J. Weissman, MD MedStar Health Research Institute & Professor of Medicine Georgetown University Washington, D.C. No Disclosures

More information

Do we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD

Do we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer

More information

Advanced MR Imaging in Myocarditis

Advanced MR Imaging in Myocarditis Naeem Merchant MD FRCP Professor of Medicine Department of Radiology Department of Cardiac Sciences Cumming School of Medicine University of Calgary Advanced MR Imaging in Myocarditis The Lake Louise Criteria

More information

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED) A Light in the Dark: Cardiac MRI and Risk Mitigation J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED) Dr. Mikolich has NO financial disclosures relative to

More information

Tissue Doppler and Strain Imaging. Steven J. Lester MD, FRCP(C), FACC, FASE

Tissue Doppler and Strain Imaging. Steven J. Lester MD, FRCP(C), FACC, FASE Tissue Doppler and Strain Imaging Steven J. Lester MD, FRCP(C), FACC, FASE Relevant Financial Relationship(s) None Off Label Usage None a. Turn the wall filters on and turn down the receiver gain. b. Turn

More information

Load and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic

Load and Function - Valvular Heart Disease. Tom Marwick, Cardiovascular Imaging Cleveland Clinic Load and Function - Valvular Heart Disease Tom Marwick, Cardiovascular Imaging Cleveland Clinic Indications for surgery in common valve lesions Risks Operative mortality Failed repair - to MVR Operative

More information

Case Study in Cancer and Cardiotoxicity

Case Study in Cancer and Cardiotoxicity Case Study in Cancer and Cardiotoxicity JEAN-BERNARD DURAND, M.D., FCCP, FACC ASSOCIATE PROFESSOR OF MEDICINE MEDICAL DIRECTOR CARDIOMYOPATHY SERVICES UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER HOUSTON,

More information

Ejection Fraction in Heart Failure: A Redefinition. Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA

Ejection Fraction in Heart Failure: A Redefinition. Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA Ejection Fraction in Heart Failure: A Redefinition Tarek Kashour King Fahad Cardiac Center King Saud University Riyadh, KSA Word of caution!!! Incomplete understanding of a disease process may lead to

More information

Strain imaging in children: from Tissue Doppler to 3 D

Strain imaging in children: from Tissue Doppler to 3 D Strain imaging in children: from Tissue Doppler to 3 D Mark kk. Friedberg Fi Outline Deformation in the fetus and neonate Deformation in pediatric cardiomyopathy y (briefly!) Deformation in Congenital

More information

THE NEW PLACE OF CARDIAC MRI IN AERONAUTICAL FITNESS

THE NEW PLACE OF CARDIAC MRI IN AERONAUTICAL FITNESS 88 th ASMA ANNUAL SCIENTIFIC MEETING DENVER - CO April 30- May 4, 2017 THE NEW PLACE OF CARDIAC MRI IN AERONAUTICAL FITNESS S. BISCONTE (1), J. MONIN (2), N. HUIBAN (3), G. GUIU (2), S. NGUYEN (1), O.

More information

Klinische Anwendung und neue Entwicklungen: Welches Verfahren für welche Indika:on? Kardiales MR. 17. Zürcher Herzkurs

Klinische Anwendung und neue Entwicklungen: Welches Verfahren für welche Indika:on? Kardiales MR. 17. Zürcher Herzkurs Klinische Anwendung und neue Entwicklungen: Welches Verfahren für welche Indika:on? Kardiales MR 17. Zürcher Herzkurs 28.09.2017 Dr. med. Gabriella De Pasquale HerzGefässZentrum Zürich Klinik im Park Most

More information

Heart Transplantation is Dead

Heart Transplantation is Dead Heart Transplantation is Dead Alternatives to Transplantation in Heart Failure Sagar Damle, MD University of Colorado Health Sciences Center Grand Rounds September 8, 2008 Outline Why is there a debate?

More information

Global left ventricular circumferential strain is a marker for both systolic and diastolic myocardial function

Global left ventricular circumferential strain is a marker for both systolic and diastolic myocardial function Global left ventricular circumferential strain is a marker for both systolic and diastolic myocardial function Toshinari Onishi 1, Samir K. Saha 2, Daniel Ludwig 1, Erik B. Schelbert 1, David Schwartzman

More information